Lv4
638 积分 2024-06-28 加入
Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
1个月前
已完结
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer
1个月前
已完结
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD
1个月前
已完结
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
1个月前
已完结
TROP2-directed antibody-drug conjugates: new first-line treatment for all patients with advanced triple-negative breast cancer?
1个月前
已完结
Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers
2个月前
已完结
Payload Diversification Overcomes Resistance and Guides Sequential Antibody–Drug Conjugate Therapy in Breast Cancer
3个月前
已完结
Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience
4个月前
已完结
Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic Review
4个月前
已完结
BAT mitochondria: whitening meets softening
1年前
已采纳
Tripeptide armour shields encapsulated proteins
1年前
已采纳
Tripeptide armour shields encapsulated proteins
1年前
已采纳
Tripeptide armour shields encapsulated proteins
1年前
已采纳
Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
1年前
已撤回
Colibactin‐positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer
1年前
已采纳
Gastric precancerous process in a high risk population: cohort follow-up
1年前
已采纳
皖公网安备34019202002308
